Snigdha Vallabhaneni, MD, MPH, discusses candidemia mortality rates in low- and middle-income versus developed countries.
Snigdha Vallabhaneni, MD, MPH, Medical Epidemiologist, Mycotic Diseases Branch at the Centers for Disease Control and Prevention, discusses candidemia mortality rates in low- and middle-income versus developed countries.
Interview Transcript (slightly modified for readability)
“Mortality with candidemia, from any species, is about 30% to 50%, and it’s higher in low- and middle-income countries, and a little bit on the lower end in the developed world. In the US it’s about 30%, and that’s about the rate of mortality we’ve been seeing with Candida auris.
We still haven’t elucidated risk factors for what, specifically, would cause death. I think the severity of the underlying illness is probably the best predictor. It’s possible that resistant isolates, because it’s harder to treat them, may be a risk factor for death, but we don’t know that yet.”
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.